Pfizer, Inc. (PFE)

Changes in reimbursement as health care costs are rationalized.

Expect profit taking following recent run-up in market as well as possible FDA withdrawal of approval of one of their pain medications.

I have owned this stock for 5+ years. It has been a dismal performer and I believe it will continue to do so. They have been behind the curve on new blockbuster drugs and don't seem to have the ability to get their R&D back to the forefront of pharma development.

Current management is making terrible decisions. Need to replace the CEO and get back to what made PFE great in the 90s.

No pipe line

Another competitor of mine during the years that I followed the white stripe as an animal health drug rep. This is a
cold-blooded company that will survive tough times. I bought in for the dividend. It will trail the S&P for the foreseeable
future because of the uncertainty of the proposed National Health Plan.

paid to much for wyeth with duplication in products. With the psychosis in DC who knows what the gub ment to a "evil" business

Pharaceuticals will suffer under this administration's plan for universal care

They are cutting the div in half to pay for the merger

I'm so mad at Pfizer! We're going to flounder at the bottom of the well! The least they could have done for their stockholders after a boner like buying Wyeth, was to give us the remainder of the dividend in stock! As soon as I can, I'm selling Pfizer and replacing it with Bristol-Meyers. Now there's an up and coming company!

Woof Woof. Market up 200 points today and this dog of a stock is still down.

You know, this really hurts for me to write this. I followed this stock for weeks, at one point was close to investing in it. I mean it had a great balance sheet, tons of cash, the maker of Viagra and Lipitor and near its 52 wk low, nice dividend to boot...

Then came Wyeth: No cash, no dividend, more debt and long term issues (upcoming expirations of blockbuster drugs) still left unresolved.

They are betting the house on finding a new blockbuster in the Alzheimer's industry. With fewer employees, fewer scientists, and an FDA more stringent in new drug approvals than ever. If you want to join Pfizer in this at best long shot gamble then good luck and God Bless you, you'll need it.

But I will most definitely not join Pfizer in this gamble.

In the short term it is possible that a market rally might send this stock up for a bit; which presents a great opp. for longs to sell through whatever strength this company has left. As 2011 approaches and the patents expire, all bets are off.

I wasted a lot of time following this stock; just happy it wasn't my money as well.

The acquisition of Wyeth is like putting a bandaid on an amputated limb. Unless dramatic changes are made to the internal structure and culture the pipelines will never be replenished.

Pfizer has nothing in the pipeline that will add value. The last two acquisitions have been disasters and management haven't dumped enough of dross they picked up along the way. Pfizer (and now Wyeth) people are facing years of job uncertainty and as Pfizer has proved beyond doubt this kills your productivity, especially in R&D. Since this is a research based company the way it's being managed is like breaking yours legs before running a marathon and still expecting to win. When Pfizer stock drops below $14 they will be acquired and asset stripped and management will wonder why. Failure to deliver products, failure to deliver stability and now failure to deliver value to shareholders is about as bad as it gets. Serious changes and more more commercial (non science based) management are needed.

Lack of new drugs in the pipeline; will survive the crisis slightly scathed.

Pfizer is sitting on a pile of cash because they received 16 billion from J&J for their OTC franchise. Pfizer hasn't made the necessary cuts in it's sales force to manage the bottom line and it's excessive overhead.

PFE is a solid company with little debt and a nice chunk of cash. The problem, as others have mentioned, is the end of the patent. There also does not seem to be any new drugs in the pipeline - that can change quickly with an unexpected breakthrough. However, even taking that into consideration I don't see PFE outperforming the S&P. If you are going to buy them, but them for the consistent dividend payout (the most resent their 281st consecutive I believe).

so lots of good things are happen to this company, but they haven't recovered from the blockbuster business model and there's about one potential drug in the pipeline and a whole lot of expiring patents. Longterm I see growth, shortterm, lots of pain medication and suffering.

Prospects don't look good right now, but with an incredible hord of cash on the balance sheet, a solid dividend (+7%) and a price to book ratio of 1.5, I suppose that the margin of safety is not that bad...

Losing the patent Lipitor in 2011 and the push for controls on drug costs will lead to more generics being nearly mandated by insurance companies and perhaps even medicare and medicaid. No blockbuster drugs in the pipeline either.